DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCorporate Action

Eris Lifesciences Limited — Appointment

NSE 1 hr ago·21 Sept 2026, 3:39 am

ERIS Lifesciences

Eris Lifesciences has announced the appointment of a new Non-Executive Independent Director, set to take effect on September 26, 2026. This appointment is part of the company's regular governance practices to strengthen its board structure.

For investors, this development is a routine corporate update. A new independent director typically brings fresh perspectives to the board, which can be beneficial for long-term corporate governance and strategic oversight. It signals the company's commitment to maintaining a robust and balanced leadership team.

Investors should monitor the background and expertise of the new appointee. This information will help assess how the new director might contribute to the company's future strategy and governance standards.